Quarterly report · Q3
9987.TEDINET S100STF5
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.81T | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.76T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥26.5bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥24.4bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥29.0bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥27.3bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥37.1bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥27.0bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥25.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥18.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥25.5bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥18.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.30T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.30T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥893.1bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥411.1bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥412.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥178.6bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥310.3 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.63 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥208.46 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.55 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 31.5% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.6% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥12m |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥39.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥8.8bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥30.4bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.2bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥199.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥22.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥177.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥808m |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.75T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.71T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥39.2bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥22.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥2.06T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥1.81T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥247.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥26.6bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥73.4bn |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥6m |
| jpcrp040300-q3r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥36.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥9.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥27.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.6bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥161.0bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥21.7bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥139.3bn |
| jpcrp040300-q3r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥854m |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.69T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.65T |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥38.8bn |
| jpcrp040300-q3r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥20.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥1.96T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥1.76T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥205.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥24.3bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 354
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任監査法人ト ー マ ツ | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)西 松 真 人 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)増 見 彰 則 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)石 原 由 寛 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 1757925000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 1814322000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 2314828000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 27289000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 29042000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 36376000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 18161000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 25497000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 20345000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 20387000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 26813000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 19170000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 412723000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 411147000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 411525000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 1304207000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 1304268000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 1146097000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 208.46 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 310.30 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 236.47 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.316 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.315 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.359 | |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 85.55 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 118.63 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 82831904 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 82831904 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 82831904 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 82831904 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 66000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 82563400 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 825634 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 202504 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 82831904 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 825634 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 66000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |